sh-Polypeptide-71 for Hair Regrowth

Created on 11/12/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

sh-Polypeptide-71, a lab-made copy of a nerve-released signaling peptide, is a cosmetic ingredient in hair and lash products marketed for thicker hair. Human evidence is thin and indirect: small studies tested it only mixed with other proteins, delivered by microneedling or laser. Risks appear low but poorly documented. For adults willing to follow demanding routines, it remains an unproven add-on whose benefit, if any, cannot yet be separated from delivery. (Full Review)

Protocol

Studied regimen (microneedling-assisted)
Twice weekly for 16–20 weeks
A vial of HR3 Matrix Hair Solution Alpha stamped into the scalp with a light-emitting device (Hairgen Booster)
Studied regimen (laser-assisted)
Three laser sessions 6 weeks apart
1927 nm thulium laser, each followed by in-office KeraFactor serum, plus a daily home scalp solution and shampoo
Leave-on serums and shampoos (marketed alternative)
As directed by manufacturers
No published regimens; penetration of a peptide this size through intact skin is unlikely
Time to effect
Increased Scalp Hair Density (microneedling-assisted)
16–20 weeks
Absence of change by 20 weeks suggests a non-response
Increased Scalp Hair Density (laser-assisted)
1 and 6 months
After treatment, in the randomized pilot trial
Increased Hair Shaft Thickness
6 months
Laser plus serum, in the randomized pilot trial

Benefits

Contraindications
  • People with previous granulomatous or allergic reactions to products needled into skin
  • People with active scalp infection, open wounds or flaring psoriasis or eczema at the application site (needle-assisted use; no human data)
  • People with bleeding disorders or on full anticoagulation (needle-assisted use; no human data)
  • People prone to keloids (no human data)
  • Pregnant or breastfeeding people (no human data)
  • People with symptomatic low blood pressure (no topical data)
  • People allergic to any product ingredient, such as polysorbates
Key Interactions
Theoretical (inferred from mechanism)
  • Topical minoxidil: may cause more stinging and greater absorption on freshly needled scalp
  • Blood pressure–lowering drugs (amlodipine, oral minoxidil) and PDE5 inhibitors (such as tadalafil): additive vessel widening could lower blood pressure if the peptide is absorbed
  • Anticoagulants (warfarin, apixaban) and antiplatelet drugs (clopidogrel): prolonged pinpoint bleeding and bruising from microneedling
  • Over-the-counter NSAIDs (aspirin, ibuprofen): more bleeding and bruising at needle sites
  • Over-the-counter scalp irritants (adapalene, salicylic acid shampoos): increased irritation
  • Bleeding-related supplements (fish oil, Ginkgo biloba): more bleeding at needle sites
  • Nitric-oxide-raising supplements (L-arginine, beetroot nitrate): additive vessel widening; possible lightheadedness if the peptide is absorbed
  • Other scalp procedures (platelet-rich plasma, other peptide serums): cumulative skin injury; regrowth impossible to attribute

Risk & Side Effects

  • High:
  • Medium:
  • Low: Microneedling-related scalp irritation; granulomatous or allergic reactions to needled products; flushing, low blood pressure and diarrhea from systemic exposure
  • Speculative:

Monitoring

Marker Target Why
Hair density (phototrichogram, hairs/cm²) No established target; track change from own baseline Expected to change
SALT score (alopecia areata only) No established target; track change from own baseline Expected to change (speculative)
Blood pressure and pulse Pulse 60–100 beats per minute; blood pressure: no established target, compare with own pre-treatment reading Safety check

Cadence: Baseline phototrichogram, standardized global scalp photographs and hair-loss stage, plus SALT score in alopecia areata and resting blood pressure and pulse if blood pressure is low or variable; blood pressure after the first two sessions if flushing or lightheadedness occurs; phototrichogram and photographs at 8 weeks, 16–20 weeks and every 6 months thereafter if use continues

Qualitative Assessment

  • Visible scalp coverage in standardized photographs
  • Shedding during washing or brushing
  • Hair shaft feel and thickness
  • Scalp comfort, redness or nodules after sessions